The U.S. Food and Drug Administration has approved palbociclib in combination with trastuzumab, with or without pertuzumab, and endocrine therapy as maintenance treatment for certain adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer.
The approval applies following induction treatment in patients whose disease has not progressed.
The approval was supported by the PATINA study, which evaluated whether adding palbociclib to HER2-directed treatment and endocrine therapy could improve outcomes.
Patients were assigned to receive either:
The primary outcome was investigator-assessed progression-free survival.
The palbociclib-based regimen demonstrated a statistically significant improvement in progression-free survival compared with HER2-directed therapy and endocrine therapy alone.
Overall-survival results were not mature when the progression-free survival analysis was conducted.
The approval introduces an additional maintenance-treatment approach for a specific population of patients with HR-positive, HER2-positive advanced breast cancer.
It also reflects continued scientific interest in combining CDK4/6 inhibition, HER2-directed therapy, and endocrine therapy within this treatment setting.
The FDA prescribing information includes important warnings and precautions. Healthcare professionals should consult the complete approved prescribing information when making treatment decisions.
View Original FDA Source ↗This summary is provided for scientific and educational awareness and is intended primarily for healthcare professionals.
It does not constitute medical advice, prescribing guidance, or product promotion. Regulatory approval, indications, and product availability may vary by country. Treatment decisions should be made by qualified healthcare professionals using locally approved prescribing information.
